“Global Translational Regenerative Medicine market set to grow to $95bn by 2024” says new Visiongain report

05 April 2019
Pharma

Visiongain has published a new pharma report Top 25 Translational Regenerative Medicine Manufacturers 2019: Medtronic, Acelity, Integra Lifesciences, NuVasive, Orthofix International, Anika Therapeutics, Organogenesis, UniQure, TiGenix, Vericel Corporation, Other Companies.

In 2018, the global translational regenerative medicine is estimated at $28bn. The global translational regenerative medicine market is highly competitive and fragmented with the presence of several vendors. The competition is likely to increase with advances in R&D and technological innovations. The market is characterized by the presence of well-diversified international and local vendors that provide cost-effective products with limited features and functionalities.

This report profiled the selected companies: Medtronic, Acelity, Integra Lifesciences, NuVasive, Orthofix International, Anika Therapeutics, Organogenesis, UniQure, TiGenix, Vericel Corporation and other companies.

The lead analyst commented that "Advancements in biological sciences have shown a positive influence on the regenerative medicine market. There are new technological advancements in terms of drug manufacturing, development, and delivery. Many cell therapy products based on mesenchymal stem cells are available in the market because of their self-renewal ability and their presence in almost all tissues. The discovery of novel scaffolds and various growth and control factors have shown promising results in stimulating tissue formation. This has led to a shift in the focus to regenerative therapies over conventional methods of treatment."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Oncology remains the largest disease area in the pharmaceutical business. The oncology market is dominated by big pharma companies and high price labels” says Visiongain report

Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.

10 September 2019

Read

“Anti-Infective Agents market set to grow to $141bn by 2024” says new Visiongain report

The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.

09 September 2019

Read

“Global thyroid gland disorder treatment market is anticipated to grow at a lucrative CAGR of 3.6% and anticipated to reach USD 3.21 Billion by 2029”, says Visiongain report.

Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.

05 September 2019

Read

“Global somatostatin analogs market is anticipated to grow at a lucrative CAGR of 5.3% and anticipated to reach USD 4.78 Bn by 2029”, says Visiongain report.

Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.

05 September 2019

Read